scholarly journals PCN197 - COST UTILITY ANALYSIS OF FIRST-LINE PACLITAXEL WITH CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB VERSUS PEMETREXED WITH CARBOPLATIN FOLLOWED BY MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER IN LEBANON

2018 ◽  
Vol 21 ◽  
pp. S47
Author(s):  
A. Tfayli ◽  
F. Elias ◽  
F. Farhat ◽  
R. Slim ◽  
Z. Hallal ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cost Utility ◽  
Small Cell ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Small Cell Lung ◽  
First Line

Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer

2019 ◽  
Vol 15 (2) ◽  
pp. 181-191
Author(s):  
Hao Wang ◽  
Chenxin Zeng ◽  
Xin Li ◽  
Youjie Wang ◽  
Xinyi Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cost Utility ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Egfr Mutated ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document